Literature DB >> 26906719

Chinese medicine syndromes in congestive heart failure: A literature study and retrospective analysis of clinical cases.

Xiao-Qian Li1, Jian-Cheng He2, Pin-Xian Huang1, Xue-Bin Cao3.   

Abstract

OBJECTIVE: To discuss the characteristics of Chinese medicine (CM) syndrome factors and distribution of congestive heart failure (CHF), and provide a basis for the diagnosis criteria of essential syndromes.
METHODS: Based on databases of China National Knowledge Infrastructure (CNKI, 1980-2012) and Chinese Journal of Chongqing VIP Database (1989-2012), the eligible studies in CHF and extracted factors associated with compound syndromes were analyzed. All the syndromes were classified into deficiency, excess, and deficiency-excess in complexity syndrome were classified. Compound syndromes were separated into syndrome factors including single, double, three or four factors, along with the frequency of occurrence. The relation of CHF syndromes with age, gender, primary disease, brain natriuretic peptide (BNP) and cardiac functional grade was studied in 1,451 CHF cases (between December 2010 and September 2012), and the clinical distribution of common CHF syndromes was summarized.
RESULTS: The literature study involved 6,799 CHF cases in 66 literatures after screening. Of the different factors affecting CHF, qi deficiency was the most important one. In deficiency syndrome, Xin (Heart)-qi-deficiency was the most common single factor, and deficiency of both qi and yin was the most common double factor. The retrospective analysis involved 1,451 CHF cases (431 cases with test results of BNP). The xin blood stasis and obstruction and deficiency of both qi and yin syndrome were mostly seen in female patients, and phlegm-blocking-Xin-vessel and qi-deficiency-blood-stasis syndrome mostly in males. Xin-qi-deficiency and qi-deficiency-blood-stasis syndrome were mostly seen in patients aged 50-60 years. Patients aged over 60 years likely manifest deficiency of both qi and yin and Xin blood stasis and obstruction syndrome. The severity of syndrome is aggravated with increased BNP and cardiac functional grade.
CONCLUSIONS: The essential syndromes of CHF include qi-deficiency-blood-stasis and deficiency of both qi and yin. The clinical distribution is linked to patients' age and gender. BNP and cardiac functional grade is closely related to CHF syndromes, which may indicate the severity of CM syndromes of CHF.

Entities:  

Keywords:  Chinese medicine; congestive heart failure; literature study; retrospective analysis of clinical cases; syndrome discipline

Mesh:

Substances:

Year:  2016        PMID: 26906719     DOI: 10.1007/s11655-015-2085-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  3 in total

1.  A new natriuretic peptide in porcine brain.

Authors:  T Sudoh; K Kangawa; N Minamino; H Matsuo
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

2.  Clinical uses of brain natriuretic peptide in diagnosing and managing heart failure.

Authors:  Kelley M Anderson
Journal:  J Am Acad Nurse Pract       Date:  2008-06

3.  [Effect of clinical pathways based on integrative medicine for patients with chronic heart failure: a multi-center research].

Authors:  Xu Zou; Guang-Ming Pan; Xiao-Gang Sheng; Geng-Zhen Yao; Ming-Jun Zhu; Yang Wu; Xiao-Hu Chen; Yong-Xia Wang; Jie Cui; Jian-Dong Chen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2013-06
  3 in total
  2 in total

1.  Tongguan Capsule Mitigates Post-myocardial Infarction Remodeling by Promoting Autophagy and Inhibiting Apoptosis: Role of Sirt1.

Authors:  Shuai Mao; Peipei Chen; Ting Li; Liheng Guo; Minzhou Zhang
Journal:  Front Physiol       Date:  2018-05-22       Impact factor: 4.566

2.  Exploring the mechanism of Shengmai Yin for coronary heart disease based on systematic pharmacology and chemoinformatics.

Authors:  Yan Jiang; Qi He; Tianqing Zhang; Wang Xiang; Zhiyong Long; Shiwei Wu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.